Rani Therapeutics: ‘We’ve Tested A Dozen Molecules, All Of Them Have Worked’
CEO Talat Imran: ‘I Think We Get An Inbound Partner Interest Every Week At This Point’
Executive Summary
In an exclusive interview with Generics Bulletin, Talat Imran, CEO of oral-dose biologics player Rani Therapeutics, talks adalimumab, partnering opportunities and financing, in the wake of kicking off pre-clinical development of its RT-111 proposed biosimilar to Janssen’s Stelara (ustekinumab) contained in its proprietary RaniPill Go ‘robotic’ capsule.